Abbott Laboratories (NYSE: ABT) stock closed at 111.82 per share at the end of the most recent trading day (a 1.15% change compared to the prior day closing price) with a volume of 4.51M shares and market capitalization of 194.41B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 109000 people. Abbott Laboratories CEO is Robert B. Ford.

The one-year performance of Abbott Laboratories stock is -14.01%, while year-to-date (YTD) performance is 1.85%. ABT stock has a five-year performance of 81.26%. Its 52-week range is between 93.25 and 130.935, which gives ABT stock a 52-week price range ratio of 48.43%

Abbott Laboratories currently has a PE ratio of 25.40, a price-to-book (PB) ratio of 5.49, a price-to-sale (PS) ratio of 5.83, a price to cashflow ratio of 19.30, a PEG ratio of 2.32, a ROA of 11.66%, a ROC of 15.73% and a ROE of 24.34%. The company’s profit margin is 17.58%, its EBITDA margin is 29.30%, and its revenue ttm is $33.56 Billion , which makes it $19.25 revenue per share.

Of the last four earnings reports from Abbott Laboratories, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.90 for the next earnings report. Abbott Laboratories’s next earnings report date is -.

The consensus rating of Wall Street analysts for Abbott Laboratories is Strong Buy (1.41), with a target price of $118.53, which is +6.29% compared to the current price. The earnings rating for Abbott Laboratories stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Abbott Laboratories has a dividend yield of 1.82% with a dividend per share of $2.04 and a payout ratio of 45.00%.

Abbott Laboratories has a Buy technical analysis rating based on Technical Indicators (ADX : 9.34, ATR14 : 2.01, CCI20 : -45.17, Chaikin Money Flow : 0.01, MACD : 0.54, Money Flow Index : 37.56, ROC : -1.49, RSI : 54.28, STOCH (14,3) : 50.60, STOCH RSI : 0.78, UO : 52.64, Williams %R : -49.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Abbott Laboratories in the last 12-months were: Andrea F. Wainer (Sold 456 shares of value $53 866 ), Christopher J. Calamari (Sold 706 shares of value $83 414 ), Daniel Gesua Sive Salvadori (Sold 1 550 shares of value $183 165 ), Daniel J. Starks (Sold 150 000 shares of value $15 990 972 ), Fernando Mateus (Sold 2 457 shares of value $267 943 ), Gregory A. Ahlberg (Sold 1 099 shares of value $129 847 ), Hubert L. Allen (Sold 1 450 shares of value $171 348 ), Jared L. Watkin (Sold 1 038 shares of value $122 589 ), John F. Ginascol (Sold 11 000 shares of value $1 235 520 ), Joseph J. Manning (Option Excercise at a value of $2 043 110), Joseph J. Manning (Sold 50 685 shares of value $5 378 990 ), Julie L. Tyler (Sold 715 shares of value $82 714 ), Lisa D. Earnhardt (Sold 943 shares of value $111 416 ), Louis H. Morrone (Sold 656 shares of value $77 513 ), Michael D. Dale (Sold 5 053 shares of value $592 413 ), Nancy Mckinstry (Option Excercise at a value of $187 394), Nancy Mckinstry (Sold 1 614 shares of value $187 910 ), Randel W. Woodgrift (Option Excercise at a value of $1 065 600), Randel W. Woodgrift (Sold 24 964 shares of value $2 825 952 ), Robert B. Ford (Option Excercise at a value of $4 121 870), Robert B. Ford (Sold 102 425 shares of value $10 765 154 ), Sammy Karam (Sold 4 200 shares of value $456 750 )